WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 327029

CAS#: 956483-02-6

Description: Valnivudine, also known as FV-100, is a potential fast-acting, once-daily therapy for herpes zoster (shingles) and for the reduction of shingles-associated pain and post-herpetic neuralgia (PHN). The small-molecule compound has been shown to more potently inhibit the replication of varicella zoster virus (VZV) substantially faster than other antivirals currently approved for the treatment of shingles, including aciclovir, famciclovir, and valaciclovir.

Price and Availability




Valnivudine (FV-100) is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 327029
Name: Valnivudine
CAS#: 956483-02-6
Chemical Formula: C27H35N3O6
Exact Mass: 497.2526
Molecular Weight: 497.592
Elemental Analysis: C, 65.17; H, 7.09; N, 8.44; O, 19.29

Synonym: Valnivudine; FV100; FV-100; FV 100

IUPAC/Chemical Name: ((2R,3S,5R)-3-hydroxy-5-(2-oxo-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-3(2H)-yl)tetrahydrofuran-2-yl)methyl L-valinate


InChi Code: InChI=1S/C27H35N3O6/c1-4-5-6-7-17-8-10-18(11-9-17)21-12-19-14-30(27(33)29-25(19)36-21)23-13-20(31)22(35-23)15-34-26(32)24(28)16(2)3/h8-12,14,16,20,22-24,31H,4-7,13,15,28H2,1-3H3/t20-,22+,23+,24-/m0/s1

SMILES Code: N[C@@H](C(C)C)C(OC[C@H]1O[C@@H](N2C=C3C(OC(C4=CC=C(CCCCC)C=C4)=C3)=NC2=O)C[C@@H]1O)=O

Technical Data

Light yellow to yellow solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: De Clercq E. An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014. Acta Pharm Sin B. 2015 Nov;5(6):520-43. doi: 10.1016/j.apsb.2015.09.001. Epub 2015 Nov 2. Review. PubMed PMID: 26713268; PubMed Central PMCID: PMC4675811.

2: De SK, Hart JC, Breuer J. Herpes simplex virus and varicella zoster virus: recent advances in therapy. Curr Opin Infect Dis. 2015 Dec;28(6):589-95. doi: 10.1097/QCO.0000000000000211. PubMed PMID: 26524331.

3: Andrei G, Snoeck R. Advances in the treatment of varicella-zoster virus infections. Adv Pharmacol. 2013;67:107-68. doi: 10.1016/B978-0-12-405880-4.00004-4. Review. PubMed PMID: 23886000.

4: De Clercq E. A cutting-edge view on the current state of antiviral drug development. Med Res Rev. 2013 Nov;33(6):1249-77. doi: 10.1002/med.21281. Epub 2013 Mar 11. Review. PubMed PMID: 23495004.

5: De Clercq E. Selective anti-herpesvirus agents. Antivir Chem Chemother. 2013 Jan 23;23(3):93-101. doi: 10.3851/IMP2533. Review. PubMed PMID: 23343513.

6: Hong SA, Kim K, Kim MK. Trends in the inequality of fruit and vegetable consumption between education levels indicated by the Korea National Health and Nutrition Examination Surveys. Eur J Clin Nutr. 2012 Aug;66(8):942-9. doi: 10.1038/ejcn.2012.39. Epub 2012 Apr 25. PubMed PMID: 22535135.

7: De Clercq E. Ten paths to the discovery of antivirally active nucleoside and nucleotide analogues. Nucleosides Nucleotides Nucleic Acids. 2012 Apr;31(4):339-52. doi: 10.1080/15257770.2012.657383. PubMed PMID: 22444195.

8: Price NB, Prichard MN. Progress in the development of new therapies for herpesvirus infections. Curr Opin Virol. 2011 Dec;1(6):548-54. doi: 10.1016/j.coviro.2011.10.015. Review. PubMed PMID: 22162744; PubMed Central PMCID: PMC3230035.

9: Andrei G, Snoeck R. Emerging drugs for varicella-zoster virus infections. Expert Opin Emerg Drugs. 2011 Sep;16(3):507-35. doi: 10.1517/14728214.2011.591786. Epub 2011 Jun 24. Review. PubMed PMID: 21699441.

10: Pentikis HS, Matson M, Atiee G, Boehlecke B, Hutchins JT, Patti JM, Henson GW, Morris A. Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers. Antimicrob Agents Chemother. 2011 Jun;55(6):2847-54. doi: 10.1128/AAC.01446-10. Epub 2011 Mar 28. PubMed PMID: 21444712; PubMed Central PMCID: PMC3101458.